PrimeRFP SCOUT · Federal Contract Recompete Brief

36C25626N0492XOFIGO RADIUM 223 for CANCER treatment — Bayer Healthcare Pharmaceuticals Inc

Bayer Healthcare Pharmaceuticals Inc holds $14.3M across 87 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent 36F79720D0237. The prior award was single-bid — competitive dynamics may favor a challenge. Recompete timing centers on the Apr 9, 2027 PoP end — agencies typically plan 12–18 months ahead.

256-Network Contract Office 16 (36C256)

Awarding office

Bayer Healthcare Pharmaceuticals Inc

Recipient

Apr 9, 2027

PoP end

$387K

Obligated

$387K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Bayer Healthcare Pharmaceuticals Inc — $90

Contract facts

Federal

Contract number36C25626N0492

Also listed as36C256-26-N-0492

Also listed as36F79720D0237-36C25626N0492

Agency256-Network Contract Office 16 (36C256)

Awarding office256-Network Contract Office 16 (36C256)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentBayer Healthcare Pharmaceuticals Inc

CAGE59463

UEIV1EVGCK7XES8

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79720D0237

Place of performanceDUBLIN OH

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startApr 10, 2026

PoP end (current)Apr 9, 2027

Obligated$387K

Current value$387K

Potential value$387K

XOFIGO RADIUM 223 FOR CANCER TREATMENT. is a federal award for 256-Network Contract Office 16 (36C256) held by Bayer Healthcare Pharmaceuticals Inc. Estimated value $387K ($387K obligated). Current period of performance ends Apr 9, 2027. Last award drew 1 bidder. Place of performance: DUBLIN OH.

Recompete timing

Public

● Expiring in 230 days

Current PoP ends Apr 9, 2027 (230 days remaining). Agencies typically plan 12–18 months ahead — at 7.6 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Bayer Healthcare Pharmaceuticals Inc — $14.3M obligated across 87 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($14.3M) · all agencies

Department of Health and Human Services (HHS)$15.1M · 106%Department of Defense (DOD)$387K · 3%Department of Justice (DOJ)$345K · 2%

Open full company profile →

Related awards

Same parent · incumbent

75A50325F80035

PURCHASE CIPROFLOXACIN 250MG/5ML ORAL SUSPENSION, POWDER, 100ML BOTTLE

$15.1M

Sep 29, 2026

36C26226F0163

XOFIGO - RADIUM RA 223DICHLORIDE INJ

$181K

Mar 31, 2027

SPE2D026F0101

8511938413!OTHER MEDICAL

$120K

Apr 5, 2027

36C24723F0573

RA-223 DICHLORIDE XOFIGO RADIO PHARM

$264K

Jun 30, 2028

36C25626N0126

RADIUM FOR CANCER TREATMENT

$376K

Aug 20, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C25626N0492?

36C25626N0492 (XOFIGO RADIUM 223 for CANCER treatment) is a 256-Network Contract Office 16 (36C256) award with a potential value of $387K, currently held by Bayer Healthcare Pharmaceuticals Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C256-26-N-0492?

36C256-26-N-0492 is the dashed form of PIID 36C25626N0492 (XOFIGO RADIUM 223 for CANCER treatment), held by Bayer Healthcare Pharmaceuticals Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C25626N0492?

256-Network Contract Office 16 (36C256) awarded 36C25626N0492 to Bayer Healthcare Pharmaceuticals Inc (potential $387K).

Who is the incumbent on 36C25626N0492?

Bayer Healthcare Pharmaceuticals Inc is the incumbent with $14.3M across 87 related awards in SCOUT’s public footprint. The current period of performance ends Apr 9, 2027.

When does Bayer Healthcare Pharmaceuticals Inc’s 36C25626N0492 come up for recompete?

SCOUT tracks a period-of-performance end of Apr 9, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jul 2, 2026 · refreshed monthlyLatest procurement action Apr 10, 2026